Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomea Fusion, Inc. - Common Stock
(NQ:
BMEA
)
4.230
+0.150 (+3.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
858,970
Open
4.020
Bid (Size)
4.220 (2)
Ask (Size)
4.400 (6)
Prev. Close
4.080
Today's Range
3.960 - 4.280
52wk Range
3.610 - 20.21
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 17, 2024
Via
Benzinga
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
December 17, 2024
Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.
Via
Benzinga
Performance
YTD
-71.17%
-71.17%
1 Month
-34.32%
-34.32%
3 Month
-48.73%
-48.73%
6 Month
-23.78%
-23.78%
1 Year
-72.10%
-72.10%
More News
Read More
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
December 17, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
December 16, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 12, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
November 18, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 30, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
October 15, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
October 09, 2024
Via
Benzinga
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
October 07, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
October 01, 2024
Via
Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
September 27, 2024
Via
Benzinga
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 02, 2024
Via
Benzinga
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024
July 31, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.